Trial reportThe Journal of experimental medicine2019
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Prognostic value of neutrophil to lymphocyte ratio for patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.Frontiers in oncology · 2022Pooled it
- Safety and efficacy of photobiomodulation therapy in oncology: A systematic review.Cancer medicine · 2020Pooled it
- Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.Advances in biological regulation · 2026Review
- Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors.Molecular cancer therapeutics · 2025Article
- Repurposing piroxicam enhances the antineoplastic effects of docetaxel and enzalutamide in prostate cancer cells using 2D and 3DFrontiers in cell and developmental biology · 2025Article
- Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives.Cancer prevention research (Philadelphia, Pa.) · 2024Review
- Nociceptive adenosine AInternational journal of oral science · 2024Article
- Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.Cancer research communications · 2023Article
- Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.Cellular and molecular life sciences : CMLS · 2022Review
- Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival.Cancer research communications · 2022Article
- HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.Nature reviews. Clinical oncology · 2022Review
- Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2022Review
- NSAIDs OvercomeCancers · 2022Article
- Oropharyngeal tumor cells induce COX-2 expression in peripheral blood monocytes by secretion of IL-1α.Frontiers in immunology · 2022Article
- Contribution of Genomics to the Surgical Management and Study of Oral Cancer.Annals of surgical oncology · 2021Review
- Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma.Scientific reports · 2021Article
- Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.International journal of molecular sciences · 2021Article
- Cell death in head and neck cancer pathogenesis and treatment.Cell death & disease · 2021Review
- Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers.Ecancermedicalscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Matthew L HedbergMedical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0002-2810-9724
Noah D PeyserDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Julie E BaumanDepartment of Medicine - Hematology/Oncology, University of Arizona, Tucson, AZ.
William E GoodingBiostatistics Facility, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Hua LiDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Neil E BholaDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Tian Ran ZhuDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Yan ZengDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Toni M BrandDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Mi-Ok KimDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
Richard C K JordanDepartment of Dermatology, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-2558-0537
Scott VandenBergDepartment of Pathology, University of California, San Francisco, San Francisco, CA.
Victor OlivasDepartment of Medicine, University of California, San Francisco, San Francisco, CA.
Trever G BivonaDepartment of Medicine, University of California, San Francisco, San Francisco, CA.
Simion I ChioseaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Lin WangDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Gordon B MillsDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX.
Jonas T JohnsonDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Umamaheswar DuvvuriDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Robert L FerrisDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Patrick HaDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Daniel E JohnsonDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
Jennifer R GrandisDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA jennifer.grandis@ucsf.edu.ORCID 0000-0002-1013-8965
University of California, San Francisco · USUniversity of Pittsburgh · USThe University of Texas MD Anderson Cancer Center · USUniversity of Arizona · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6MIntegrating genomics and the protein interactome for HPV+ head and neck cancer therapyR35CA231998 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2018 to 2024
$6.2MPI3K Pathway Mutations in Head and Neck CancerR01DE023685 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRANDIS, JENNIFER RUBIN, JOHNSON, DANIEL E · 2014 to 2023
$5.1MGRPR Signaling in SCCHN: Integration with EGFRR01CA098372 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRANDIS, JENNIFER RUBIN · 2004 to 2017
$3.8MImplications of Procaspase-8 Mutations in Oral Squamous Cell CarcinomaR01DE024728 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHNSON, DANIEL E · 2016 to 2020
$2.0MPhosphoinositol-3-Kinase Signaling and PIK3CA: Critical Mitogenic Drivers in HeadF30CA180235 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEDBERG, MATTHEW LOUIS · 2014 to 2016
$135kNCI NIH HHS F30 CA180235NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS R01 CA098372NCI NIH HHS R35 CA231998NIDCR NIH HHS R01 DE023685NIDCR NIH HHS R01 DE024728
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Squamous CellClass I Phosphatidylinositol 3-KinasesHead and Neck NeoplasmsMutationNeoplasm ProteinsAdultAgedAnimalsAnti-Inflammatory Agents, Non-SteroidalDisease-Free SurvivalFemaleHumansMaleMiceMice, Inbred NODMiddle AgedAnti-Inflammatory Agents, Non-SteroidalClass I Phosphatidylinositol 3-KinasesNeoplasm ProteinsPIK3CA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.